Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FDPS | P14324 | 3/20 | 0.41 |
| ▸ | CES2 | O00748 | 3/20 | 0.38 |
| ▸ | FAAH | O00519 | 8/20 | 0.38 |
| ▸ | CES1 | P23141 | 5/20 | 0.36 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | THRB | P10828 | 1/20 | 0.35 |
| ▸ | LPAR1 | Q92633 | 1/20 | 0.34 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.34 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.34 |
| ▸ | ODC1 | P11926 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL188440 | 1.00 | FDPS (0.41) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL5704613 | 1.00 | FDPS (0.41) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL21199502 | 0.87 | MEN1 (0.38) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL5704692 | 0.87 | MEN1 (0.38) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL5704688 | 0.87 | MEN1 (0.38) | FDPSCES2FAAHCES1MEN1 | |
| SCHEMBL28817817 | 0.85 | FDPS (0.42) | FDPSMEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL4812447 | 0.81 | ODC1 (0.53) | FDPSMEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL4812451 | 0.81 | ODC1 (0.53) | FDPSMEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL4812444 | 0.81 | ODC1 (0.53) | FDPSMEN1CYP1A2KMT2AALDH1A1 | |
| SCHEMBL7203565 | 0.79 | ODC1 (0.47) | FDPSMEN1CYP1A2KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 46 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | claimed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | claimed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | claimed |
| EP-4687443-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | Genepep (FR) | 2026-02-11 | — | — | EP | disclosed |
| WO-2024208878-A1 | METHOD FOR FUNCTIONALISING A SOLID SUBSTRATE WITH A PEPTIDE CONJUGATE | GENEPEP (FR) | 2024-10-10 | — | — | WO | disclosed |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2023-12-28 | — | — | US | disclosed |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | Karoyan, Philippe (FR) | 2023-09-19 | — | — | US | disclosed |
| EP-3454879-B1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | INST NAT SANTE RECH MED (FR) | 2021-12-22 | — | — | EP | disclosed |
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | PEPKON SAS (FR) | 2019-05-16 | — | — | US | disclosed |
| EP-3454879-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2019-03-20 | — | — | EP | disclosed |
| EP-3220957-B1 | CONJUGATED MOLECULES COMPRISING A PEPTIDE DERIVED FROM THE CD4 RECEPTOR COUPLED TO AN ANIONIC POLYPEPTIDE FOR THE TREATMENT OF AIDS | PASTEUR INSTITUT (FR) | 2018-11-07 | — | — | EP | disclosed |
| WO-2010023295-A1 | PIPECOLIC LINKER AND ITS USE FOR CHEMISTRY ON SOLID SUPPORT | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) (FR) | 2010-03-04 | — | — | WO | disclosed |
| US-20080249030-A1 | Age Inhibitors | CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (FR) | 2008-10-09 | — | — | US | disclosed |
| EP-1863832-A1 | AGE INHIBITORS | Pharmamens (FR) | 2007-12-12 | — | — | EP | disclosed |
| WO-2006103274-A9 | AGE INHIBITORS | PHARMAMENS (FR) | 2007-01-18 | — | — | WO | disclosed |
| EP-1303258-B1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2006-10-11 | — | — | EP | disclosed |
| WO-2006103274-A1 | AGE INHIBITORS | PHARMAMENS (FR) | 2006-10-05 | — | — | WO | disclosed |
| US-20030194378-A1 | Novel aerosol formulation containing a polar fluorinated molecule | ASTRAZENECA AB (SE) | 2003-10-16 | — | — | US | disclosed |
| EP-1303258-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | AstraZeneca AB (SE) | 2003-04-23 | — | — | EP | disclosed |
| WO-2002003958-A1 | NOVEL AEROSOL FORMULATION CONTAINING A POLAR FLUORINATED MOLECULE | ASTRAZENECA AB (SE) | 2002-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190144501-A1 | NEW COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | FDPS 1413/4885CES2 4508/4885FAAH 4466/4885 |
| US-11759496-B2 | Compounds and pharmaceutical use thereof in the treatment of cancer | VIP, RNASE1, ABCB11 | FDPS 1221/4885CES2 4240/4885FAAH 4510/4885 |
| US-20230414702-A1 | COMPOUNDS AND PHARMACEUTICAL USE THEREOF IN THE TREATMENT OF CANCER | VIP, RNASE1, ABCB11 | FDPS 1221/4885CES2 4240/4885FAAH 4510/4885 |
| US-20080249030-A1 | Age Inhibitors | CFH, XPA, XPNPEP1 | FDPS 2807/4885CES2 371/4885FAAH 105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.